For prostate cancer, a major shift in screening was made in 2012, when the large, U.S., multi-institutional Prostate, Lung, Colorectal, Ovarian (PLCO) clinical trial found prostate specific antigen (PSA) screening to be ineffective in reducing prostate cancer mortality [32, 33]. The gene discussed is KLK3; the disease is Familial prostate cancer.